2-Chlorodeoxyadenosine: A New Nucleoside Agent Effective in the Treatment of Lymphoid Malignancies

References

• Giblett E. R., Anderson J. E., Cohen F., Pollara B., Meuwissen H. J. Adenosine deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 1972; 2: 1067–1069
   PubMed Web of Science ®Google Scholar
• Carson D. A., Kaye J., Wasson D. B., et al. Deoxycytidine kinase mediated toxicity of deoxyadenosine analogs towards malignant human lymphoblasts in vivo. Proceedings of the National Academy of Sciences of the United States of America 1980; 77: 6865–6869
   PubMed Web of Science ®Google Scholar
• Carson D. A., Wasson D. B., Taetle R., Yu A. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 1983; 62(4)737–743
   PubMed Web of Science ®Google Scholar
• Seto S., Carrera C. J., Kubota M., Wasson D. B., Carson D. A. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. Journal of Clinical Investigation 1985; 75: 377–383
   PubMed Web of Science ®Google Scholar
• Seto S., Carrera C. J., Wasson D. B., Carson D. A. Inhibition of DNA repair by deoxyadenosine in resting human lymphocytes. Journal of Immunology 1986; 136: 2839–2843
   PubMed Web of Science ®Google Scholar
• Carrera C. J., Terai C., Piro L., Saven A., Beutler E., Carson D. 2-CdA phemotherapy triggers programmed cell death in normal and malignant lymphocytes. J. Purine Pyrimidine Res. 1991; 2(Suppl 1)38
   Google Scholar
• Juliusson G., Liliemark J. 2-Chlorodeoxyaden-osine (2-CdA) in lymphoproliferative diseases. Clinicial and pharmacokinetic studies. Blood 1990; 76: 354A, (Abstract)
   PubMedGoogle Scholar
• Carson D. A., Wasson D. B., Beutler E. Anti-leukemic and immunosuppressive activity of 2-chloro-2′deoxyadenosine. Proceedings of The National Academy of Sciences of the United States of America 1984; 81: 2232–2236
   PubMed Web of Science ®Google Scholar
• Saven A., Waltz T., Carrera C. J., Kawasaki H., Carson D. A., Beutler E., Piro L. D. Phase I study of 2-chlorodeoxyadenosine (2-CdA) in non-hemato-logic malignancies. Proceedings of the American Society of Clinical Oncology 1992; 119: 299
   Google Scholar
• Piro L. D., Carrera C. J., Carson D. A., Beutler E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. New England Journal of Medicine 1990; 322: 1117–1121
   PubMed Web of Science ®Google Scholar
• Piro L. D., Saven A., Ellison D., Thurston D., Carson D. A., Beutler E. Prolonged complete remissions following 2-chloredeoxyadenosine (2-CdA) in hairy cell leukemia (HCL). Proceedings of the American Society of Clinical Oncology 1992; 11: 846
   Google Scholar
• Carrera C. J., Piro L. D., Saven A., Cox K., Beutler E., Carson D. A., Kipps T. J. Restoration of lymphocyte subsets following 2-chlorodeoxyadenosine remission induction in hairy cell leukemia. Blood 1990; 76(Suppl. 1)260a, (Abstract)
   Google Scholar
• Piro L. D., Carrera C. J., Beutler E., Carson D. A. 2-chlorodeoxyadenosine: An effectrive new agent for the treatment of chronic lymphocytic leukemia. Blood 1988; 72(3)1069–1073
   PubMed Web of Science ®Google Scholar
• Saven A., Carrera C. J., Carson D. A., Beutler E., Piro L. D. 2-Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. Leukemia Lym-phoma 1991; 5(Suppl)133–138
   PubMed Web of Science ®Google Scholar
• Cheson B. D., Bennett J. M., Rai K. R., Grever M. R., Kay N. E., Schiffer C. A., Oken M. M., Keating M. J., Boldt D. H., Kempin S. J., Foon K. A. Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the National Cancer Institute-sponsored Working Group. Journal of Hematology 1988; 29: 152–163
   PubMed Web of Science ®Google Scholar
• Kay A. C., Carrera C. J., Carson D. A., Beutler E., Piro L. D. Phase II trial of 2-chlorodeoxyadenosine in low grade lymphoma. Blood 1989; 74: 121a, (Abstract)
   Google Scholar
• Kay A. C., Saven A., Carrera C. J., Carson D. A., Beutler E., Piro L. D. 2-chlorodeoxyadenosine treatment of low-grade lymphomas. Journal of Clinical Oncology 1992; 10: 371–377
   PubMed Web of Science ®Google Scholar
• Saven A., Carrera C. J., Carson D. A., Beutler E., Piro L. D. 2-Chlorodeoxyadenosine: An active agent in the treatment of cutaneous T-cell lymphoma. Blood 1992; 809: 587–592
   Google Scholar
• Kuzel T., Samuelson E., Roenigk H., Trop E., Rosen S. Phase II trial of 2-chlorodeoxyadenosine (2-CdA) for the treatment of mycosis fungoides or the Se-zary Syndrome (MF-SS). Proceedings of the American Society of Clinical Oncology 1992; 11: 1089, (Abstract)
   Google Scholar
• Petzer A. L., Bilgen R., Zilian U., et al. Inhibitory effect of 2-chlorodeoxyadenosine on granulocytic, erythroid and T-lymphocytic colony growth. Blood, 78: 2583–2587
   PubMed Web of Science ®Google Scholar
• Saven A., Figueroa M. L., Piro L. D., Beutler E. Complete hematological remissions in chronic myelogenous leukemia (CML) following 2-chlorodeoxyadenosine (2-CdA). Proceedings of the American Society of Clinical Oncology 1992; 11: 855
   Google Scholar
• Santana V. M., Mirro J. L., Jr., Kearns C., Schell M. J., Crom W., Blakley R. L. 2-Chlorodeoxy-adenosine produces a high rate of complete hematologic remissions in relapsed myeloid leukemia. Journal of Clinical Oncology 1992; 10: 364–370
   PubMed Web of Science ®Google Scholar
• Carson D. A., Wasson D. B., Esparza L. M., Carrera C. J., Kipps T. J., Cottam H. B. Oral anti-lymphocytic activity and induction of apoptosis by 2′-chloro-2′-ARA-2′-deoxyadenosine (CAFdA). Proceedings of the National Academy of Sciences of the United States of America 1992; 89: 2970–2974
   PubMed Web of Science ®Google Scholar
• Estey E. M., Kurzrock R., Kantarjian H. M., O'Brien S., McCredie K., Beran M., Koller C., Keating M., Hirsch-Ginsberg C., Huy Y. O., Stass S., Freireich E. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). Blood 1992; 79: 882–887
   PubMed Web of Science ®Google Scholar
• Juliusson G., Liliemark J. Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2′deoxyadenosine (CdA): Relation to opportunistic infections. Blood 1992; 79: 888–894
   PubMed Web of Science ®Google Scholar
• Hoffman M., Rai K., Sawitsky A., Janson D. 2-chlorodeoxyadenosine (2-CdA) in hairy cell leukemia. Blood 1991; 78(Suppl 1)454a, (Abstract)
   Google Scholar
• Tallman M., Hakimian D., Variakojis D., Kaul K., Koslow D. 2-Chlorodeoxyadenosine (2-CdA) in the treatment of hairy cell leukemia (HCL). Blood 1991; 78(Suppl 1)34a, (Abstract)
   Google Scholar
• Lauria F., Benfenati D., Zinzani P. L., Raspadori D., Rondelli D., Tura S. 2-Chlorodeoxyadenosine in the treatment of hairy cell leukemia patients relapsed after α-interferon. Blood 1991; 78(Suppl 1)34a, (Abstract)
   Google Scholar
• Santana V. M., Mirro J., Jr., Harwood F. C., Cherrie J., Schell M., Kalwinsky D., Blakley R. L. A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia. Journal of Clinical Oncology 1991; 9: 416–422
   PubMed Web of Science ®Google Scholar